No CrossRef data available.
Article contents
Evaluation of Sleeping Profile in Schizophrenia Patients Treated with Paliperidone-Extended Release: Result From an Open Labeled Perspective Study in South East Asia (Perfect Study)
Published online by Cambridge University Press: 23 March 2020
Abstract
Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objective
To evaluate the impact of treatment with paliperidone extended release for 6 months on sleeping profile in schizophrenia patients.
Methods
A total of 984 patients meeting the DSM-IV criteria for schizophrenia who switched their antipsychotics to be paliperidone ER were recruited from 61 sites in five countries in Southeast Asia. We assessed patients in terms of demographic profile, sleep quality and daytime drowsiness as visual analog scale.
Results
Patients in our studies received paliperidone ER treatment for 6 months. About 70% completed the treatment. Sleep quality and also daytime drowsiness were significantly increased in patients compared with their baseline. The predictive factors that have effect on sleep profile improvement were completion of the study and baseline PANSS score.
Conclusion
Patients receiving paliperidone ER were found to have improvement in sleep quality and also improvement in daytime drowsiness, especially in patients within completion group and the higher baseline PANSS score.
Disclosure of interest
The author has not supplied his/her declaration of competing interest.
- Type
- e-Poster Walk: Schizophrenia and Other Psychotic Disorders–Part 4
- Information
- European Psychiatry , Volume 41 , Issue S1: Abstract of the 25th European Congress of Psychiatry , April 2017 , pp. S273 - S274
- Copyright
- Copyright © European Psychiatric Association 2017
You have
Access
Comments
No Comments have been published for this article.